United Therapeutics (UTHR) Capital Expenditures (2009 - 2026)

United Therapeutics (UTHR) has 18 years of Capital Expenditures data on file, last reported at $99.6 million in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures rose 32.98% year-over-year to $99.6 million; the trailing twelve-month figure through Mar 2026 stood at $141.0 million (down 52.65% YoY), and the FY2025 full-year result was $116.3 million, down 52.82% from the prior year.
• Capital Expenditures grew to $99.6 million in Q1 2026, from -$231.3 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $281.4 million in Q3 2025 to a low of -$231.3 million in Q4 2025.
• A 5-year average of $29.1 million and a median of $18.4 million in 2023 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures soared 1044.44% in 2022 and plunged 2442.86% in 2023, its largest moves.
• Tracing UTHR's Capital Expenditures over 5 years: stood at $700000.0 in 2022, then sank by 2442.86% to -$16.4 million in 2023, then jumped by 628.66% to $86.7 million in 2024, then sank by 366.78% to -$231.3 million in 2025, then jumped by 143.06% to $99.6 million in 2026.
• Business Quant data shows UTHR's Capital Expenditures at $99.6 million in Q1 2026, -$231.3 million in Q4 2025, and $281.4 million in Q3 2025.